Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis
- PMID: 37170239
- PMCID: PMC10173666
- DOI: 10.1186/s12889-023-15749-x
Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis
Erratum in
-
Correction: Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis.BMC Public Health. 2023 Jul 18;23(1):1380. doi: 10.1186/s12889-023-15986-0. BMC Public Health. 2023. PMID: 37464293 Free PMC article. No abstract available.
Abstract
Background: Alcohol related liver disease (ARLD) is one of the major chronic liver diseases worldwide. This review aimed to describe the global prevalence, incidence, and outcomes of ARLD.
Methods: Medline, Embase, The Cochrane Library, and China National Knowledge Infrastructure (CNKI) were searched from inception to May 31, 2022. The language was restricted to English or Chinese. According to the criteria, articles describing the basic characteristics of the population were selected. Two reviewers extracted the data independently.
Results: A total of 372 studies were identified: 353 were used for prevalence analysis, 7 were used for incidence analysis, and 114 were used to for outcome analysis. The prevalence of ARLD worldwide was 4.8%. The prevalence in males was 2.9%, which was higher than female (0.5%). Among the ethnic groups, the percentage was highest in Caucasians (68.9%). Alcoholic liver cirrhosis comprised the highest proportion in the disease spectrum of ARLD at 32.9%. The prevalence of ascites in ARLD population was highest (25.1%). The ARLD population who drinking for > 20 years accounted for 54.8%, and the average daily alcohol intake was 146.6 g/d. About 59.5% of ARLD patients were current or former smokers, and 18.7% were complicated with hepatitis virus infection. The incidence was 0.208/1000 person-years. The overall mortality was 23.9%, and the liver-related mortality was 21.6%.
Conclusion: The global prevalence of ARLD was 4.8% and was affected by sex, region, drinking years, and other factors. Therefore, removing the factors causing a high disease prevalence is an urgent requisite.
Trial registration: PROSPERO Nr: CRD42021286192.
Keywords: Alcohol related liver diseases; Epidemiology; Prevalence.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Incidence and management patterns of alcohol-related liver disease in Korea: a nationwide standard cohort study.Sci Rep. 2021 Mar 23;11(1):6648. doi: 10.1038/s41598-021-86197-z. Sci Rep. 2021. PMID: 33758281 Free PMC article.
-
Development of severe alcohol related liver disease over four decades in Iceland: impact of increased access and use of alcohol.Scand J Gastroenterol. 2023 Jul-Dec;58(12):1523-1533. doi: 10.1080/00365521.2023.2245939. Epub 2023 Aug 8. Scand J Gastroenterol. 2023. PMID: 37551903
-
Alcohol misuse in patients with alcohol-related liver disease: How can we do better? A narrative review of the literature.Alcohol Clin Exp Res. 2022 Aug;46(8):1364-1370. doi: 10.1111/acer.14895. Epub 2022 Jul 8. Alcohol Clin Exp Res. 2022. PMID: 35766348 Free PMC article. Review.
-
Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests.BMJ Open. 2021 Jun 4;11(6):e047786. doi: 10.1136/bmjopen-2020-047786. BMJ Open. 2021. PMID: 34088709 Free PMC article.
-
Liver Transplantation in Alcohol-related Liver Disease and Alcohol-related Hepatitis.J Clin Exp Hepatol. 2023 Jan-Feb;13(1):127-138. doi: 10.1016/j.jceh.2022.06.013. Epub 2022 Jul 5. J Clin Exp Hepatol. 2023. PMID: 36647412 Free PMC article. Review.
Cited by
-
Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models.Front Pharmacol. 2024 Nov 28;15:1432480. doi: 10.3389/fphar.2024.1432480. eCollection 2024. Front Pharmacol. 2024. PMID: 39669199 Free PMC article. Review.
-
Contingency management to promote treatment engagement in comorbid alcohol use disorder and alcohol-related liver disease: Findings from a pilot randomized controlled trial.Alcohol Clin Exp Res (Hoboken). 2025 Apr;49(4):893-910. doi: 10.1111/acer.70018. Epub 2025 Mar 10. Alcohol Clin Exp Res (Hoboken). 2025. PMID: 40064640 Free PMC article. Clinical Trial.
-
Value of a multi-indicator model combining Elast PQ technology, blood lipids, liver function, and uric acid for early diagnosis of alcoholic fatty liver disease.Am J Transl Res. 2025 Apr 15;17(4):3050-3062. doi: 10.62347/GMGX5873. eCollection 2025. Am J Transl Res. 2025. PMID: 40385037 Free PMC article.
-
Metabolic Dysfunction-Associated Steatotic Liver Disease and Alcohol-Associated Liver Disease: Liver DNA Methylation Analysis-A Systematic Review.Cells. 2024 Nov 16;13(22):1893. doi: 10.3390/cells13221893. Cells. 2024. PMID: 39594641 Free PMC article.
-
Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease.Gut Microbes. 2024 Jan-Dec;16(1):2307586. doi: 10.1080/19490976.2024.2307586. Epub 2024 Feb 1. Gut Microbes. 2024. PMID: 38298161 Free PMC article.
References
-
- Global status report on alcohol and health 2018 [https://www.who.int/substance_abuse/publications/global_alcohol_report].
-
- Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, Xu Y, Liu Y, Li W, Koike K, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol. 2019;71(1):212–221. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical